Prosecution Insights
Last updated: April 19, 2026

Examiner: FERNANDEZ, SUSAN EMILY

Tech Center 1600 • Art Units: 1651

This examiner grants 52% of resolved cases

Performance Statistics

52.0%
Allow Rate
-8.0% vs TC avg
589
Total Applications
+60.5%
Interview Lift
1475
Avg Prosecution Days
Based on 548 resolved cases, 2023–2026

Rejection Statute Breakdown

6.0%
§101 Eligibility
11.0%
§102 Novelty
40.8%
§103 Obviousness
30.3%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17104593 PHARMACEUTICAL COMPOSITIONS FOR TREATING ACID SPHINGOMYELINASE DEFICIENCY Non-Final OA Genzyme Corporation
18033903 METHODS AND MATERIALS FOR IDENTIFYING AND TREATING MEMBRANOUS NEPHROPATHY Non-Final OA Mayo Foundation for Medical Education and Research
17924916 DE-REPRESSION OF NITROGEN FIXATION IN GRAM-POSITIVE MICROORGANISMS Non-Final OA Pivot Bio, Inc.
17572011 PRODUCING METHOD FOR ORGANISM-DERIVED MATERIAL, PRODUCING METHOD FOR PRODUCT, AND VOLTAGE APPLYING DEVICE Final Rejection FUJIFILM Corporation
17757528 SORBITAN ESTERS AND PROCESS FOR ENZYMATICALLY PREPARING SAME Non-Final OA Evonik Operations GmbH
18588937 ELECTRON BEAM IRRADIATED OSTEOINDUCTIVE BONE IMPLANT Non-Final OA WARSAW ORTHOPEDIC INC.
17628148 DEVICE AND METHODS FOR TISSUE MOLECULAR PROFILING USING ELECTROPORATION BASED MOLECULAR EXTRACTION Final Rejection Ramot at Tel-Aviv University Ltd.
17617953 METHOD FOR DETERMINING THE EFFECTIVENESS OF A STERILIZATION METHOD FOR A MEDICAL PRODUCT IN A STERILIZER, DATA PROCESSING SYSTEM, COMPUTER PROGRAM PRODUCT, AND MEDICAL PRODUCT Final Rejection FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH
18404003 CHITIN, HYDROLYSATE AND METHOD FOR THE PRODUCTION OF ONE OR MORE DESIRED PRODUCTS FROM INSECTS BY MEANS OF ENZYMATIC HYDROLYSIS Non-Final OA Ynsect
18679622 SYSTEM AND METHOD FOR METHANE BIODEGRADATION Non-Final OA Parsons Corporation
17565834 METHODS OF DIAGNOSIS, SELECTION, AND TREATMENT OF DISEASES AND CONDITIONS CAUSED BY OR ASSOCIATED WITH METHANOGENS Non-Final OA Cedars-Sinai Medical Center
18012059 Concrete with Improved Environmental Impact Final Rejection Locus Solutions IPCo, LLC
18629323 AUGMENTATION OF CELL THERAPY EFFICACY INCLUDING TREATMENT WITH ALPHA 1,3 FUCOSYLTRANSFERASE Final Rejection Targazyme, Inc.
18628352 BIOCATALYTIC MICROCAPSULES FOR CATALYZING GAS CONVERSION Non-Final OA Lawrance Livermore National Security, LLC
16339874 Normalization of the Intestinal Microbiota Composition in Infants or Toddlers Fed with an Amino Acid-Based Nutritional Composition Non-Final OA N. V. Nutricia
18431778 METHODS AND COMPOSITIONS FOR ASSAYING BETA-HEXOSAMINIDASE ENZYMATIC ACTIVITY VIA MASS SPECTROMETRY Non-Final OA GelbChem, LLC
18537002 FORMULATIONS OF POLYALKYLENE OXIDE-ASPARAGINASE AND METHODS OF MAKING AND USING THE SAME Non-Final OA SERVIER IP UK Limited
15309320 METHODS AND COMPOSITIONS FOR INDUCTION OF UCP1 EXPRESSION Non-Final OA Joslin Diabetes Center, Inc.
18278242 MICROORGANISM-DERIVED MATERIAL AND METHODS FOR PRODUCING SAME Non-Final OA YEAP LTD.
17546089 Method for ex vivo expansion CD34+HSPCs into NK cells using an aryl hydrocarbon receptor antagonist Final Rejection Stichting Radboud universitair medisch centrum
18044263 METHODS FOR LYSING BACTERIAL CELLS Final Rejection ABELZETA INC.
18075059 Combined Fluorescence and Scanning Electron Microscope System for Pathogen Detection Non-Final OA IntelliFoods Labs, LLC
17782207 EYE TOPICAL COMPOSITION CONTAINING METABOLITES OF THE FERMENTATION OF LACTOBACILLUS Non-Final OA SIFI S.P.A.
17254748 NOVEL METHOD FOR PREPARING ALPHA-LACTALBUMIN-ENRICHED COMPOSITIONS, RELATED PRODUCTS AND USES E.G. IN INFANT FORMULAS Final Rejection ARLA FOODS AMBA
17661480 SEQUENTIAL ELECTROPORATION METHODS Non-Final OA MaxCyte, Inc.
17434791 A Glutathione-Rich Yeast and Its Use for Preserving Wines Final Rejection Universite de Bourgogne
16950013 RESERVOIR TREATMENTS Non-Final OA GOE-IP AS
16806161 BIOREMEDIATION COMPOSITION WITH TIME-RELEASE MATERIALS FOR REMOVING ENERGETIC COMPOUNDS FROM CONTAMINATED ENVIRONMENTS Non-Final OA REMEDIATION PRODUCTS, INC.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month